Pharma

Your Article Summary

See Latest Articles

Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Mylan, 06/04/09

Mylan Inc.'s Chief Operating Officer Heather Bresch testified before the U.S. House of Representatives Judiciary Subcommittee on Courts and Competition Policy concerning patent litigation settlements between branded pharmaceutical companies and generic pharmaceutical companies. During her testimony, Bresch conveyed Mylan's position that the launch of an authorized generic by brand companies during a generic company's 180-day exclusivity period undermines competition and delays timely access to high quality, affordable generic medications for patients, taxpayers, the government and businesses.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Two Delivery Systems Win Baldrige Award
HealthDataManagement, 12/18/09

Advisory Committee briefing materials for CRESTOR sNDA available on US FDA web site
AstraZeneca, 12/15/09

Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09

 See all of Regulatory Issues